The study found that agency leaders almost always followed the recommendations of career scientists, repeatedly reviewed safety data, and reaffirmed that mifepristone is safe while making cautious changes to access. Polling Insights: KFF’s November 2025 Health Tracking Poll found that the public is largely divided over the intention underlying the FDA’s review of mifepristone. Public opinion data suggests the decision lands amid declining and polarized public confidence in the WHO itself. The withdrawal occurs as the U.S. public’s trust in federal health agencies has continued to erode. As global health partnerships change, health communicators may benefit from tracking changes in trust in health agencies to better understand where audiences turn to for health information.